DarioHealth (NASDAQ:DRIO) Releases Quarterly Earnings Results, Beats Estimates By $0.37 EPS

DarioHealth (NASDAQ:DRIO) issued its quarterly earnings results on Tuesday. The company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($1.22) by $0.37, FiscalAI reports. The firm had revenue of $5.18 million during the quarter, compared to the consensus estimate of $5.92 million. DarioHealth had a negative return on equity of 60.52% and a negative net margin of 192.23%.

Here are the key takeaways from DarioHealth’s conference call:

• Revenue declined to $5.2 million from $5.6 million in Q1 and $5.4 million a year ago, reflecting implementation timing and the company’s exit from pharmaceutical-services revenue. Management expects momentum to improve in Q3 and Q4, but most contracted revenue is not expected to contribute until 2027.
• DarioHealth ended Q2 with approximately $13.1 million in contracted and late-stage annual recurring revenue, more than 80% of it multi-condition, and reported over 180 signed employer and health-plan accounts. About 75% of new accounts now come through channel partners, which management says is reducing customer-acquisition costs and sales-cycle times.
• Financial efficiency improved, with gross margin rising to 62%, operating expenses falling 21% year over year, and net loss improving 39% to $7.9 million. Management expects incremental revenue from existing implementations, AI-enabled engagement, and new care offerings to generate meaningful operating leverage.
• The company launched an integrated GLP-1 program and introduced women’s health and sleep programs, expanding its provider-backed care and multi-condition platform. Dario expects DarioIQ to increase recurring revenue from existing customers by approximately 10%–15% over time through improved engagement, retention, and outcomes.
• Pro forma cash increased to $36.8 million following a July registered-direct financing, providing additional runway to execute on commercial opportunities and pursue the company’s path toward cash-flow positivity.

DarioHealth Stock Performance

NASDAQ DRIO traded up $0.04 during trading hours on Wednesday, hitting $7.71. The company’s stock had a trading volume of 7,134 shares, compared to its average volume of 15,282. DarioHealth has a 12 month low of $5.84 and a 12 month high of $17.74. The company’s 50 day simple moving average is $7.10 and its two-hundred day simple moving average is $8.30. The company has a market cap of $56.59 million, a P/E ratio of -0.87 and a beta of 1.11. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.07 and a quick ratio of 2.62.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on DRIO. Weiss Ratings reissued a “sell (e+)” rating on shares of DarioHealth in a research report on Friday, July 10th. TD Cowen decreased their target price on shares of DarioHealth from $11.00 to $8.00 and set a “hold” rating for the company in a report on Wednesday. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $10.00 target price on shares of DarioHealth in a research note on Thursday, May 14th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $9.00.

Insider Transactions at DarioHealth

In related news, Director Dennis Matheis bought 14,430 shares of the stock in a transaction on Thursday, July 23rd. The shares were acquired at an average price of $6.93 per share, for a total transaction of $99,999.90. Following the purchase, the director owned 43,026 shares of the company’s stock, valued at approximately $298,170.18. The trade was a 50.46% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 3.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. Kestra Advisory Services LLC purchased a new stake in DarioHealth in the fourth quarter worth approximately $35,000. XTX Topco Ltd raised its stake in DarioHealth by 229.0% during the 2nd quarter. XTX Topco Ltd now owns 62,511 shares of the company’s stock valued at $42,000 after buying an additional 43,513 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in DarioHealth by 167.9% during the 4th quarter. Geode Capital Management LLC now owns 49,567 shares of the company’s stock valued at $564,000 after buying an additional 31,063 shares during the last quarter. 33.39% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting DarioHealth

Here are the key news stories impacting DarioHealth this week:

• Positive Sentiment: Q2 results showed operational improvement. DarioHealth reported approximately $5.2 million in revenue, while its quarterly loss per share was narrower than analysts expected. Gross margin rose to 62% from 57% in the prior quarter and 55% a year earlier. Operating expenses fell 21% year over year, and the operating loss declined 30%. DarioHealth Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Commercial momentum strengthened. The company highlighted more than $13.1 million in contracted and late-stage annual recurring revenue, with over 80% tied to its multi-condition platform. Recent wins include an expansion with a top-five national health plan that could approximately triple the related revenue opportunity, a Fortune 50 customer and a health insurer reached through Amwell. DarioHealth Q2 2026 Earnings Call Highlights
• Positive Sentiment: Liquidity improved. DarioHealth ended the period with pro forma cash of $36.8 million after raising $22.8 million in July through an at-the-market registered direct financing, supported by existing and new institutional investors. The company also expanded into provider-backed clinical care delivery, potentially increasing revenue per customer. DarioHealth Q2 2026 Earnings Call Transcript
• Neutral Sentiment: A comparative analysis reviewed DarioHealth alongside Ascom, offering sector and business-model context but no clear new company-specific catalyst. Critical Survey: DarioHealth versus Ascom
• Neutral Sentiment: Trading was briefly halted under a limit-up/limit-down pause, indicating temporary volatility rather than a fundamental announcement.
• Negative Sentiment: Revenue remained below expectations. Quarterly revenue of roughly $5.18 million missed the approximately $5.92 million consensus estimate, partly reflecting the decision to discontinue certain pharmaceutical-related business. DarioHealth remains unprofitable, and the financing may create dilution for existing shareholders. DarioHealth Reports Q2 Loss, Lags Revenue Estimates

DarioHealth Company Profile

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.